{"entity":{"id":"nct06077877","kind":"trial","name":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Niraparib in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.","summary":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06077877 by GlaxoSmithKline, with 42 participants enrolled, started 2023-10-24 and due to reach its primary completion in 2026-06-30. Interventions recorded: GSK4524101 and Niraparib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06077877","url":"https://clinicaltrials.gov/study/NCT06077877"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["niraparib"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06077877","phase":"1/2","setting":"A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT06077877","source":"https://clinicaltrials.gov/study/NCT06077877","fetchedAt":"2026-10-07T16:54:09.016Z","studySha256":"fa6c5af947242a3047c6221c9774af3067ab5ac3c4e448aa6ea232b0c271d738","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-24","leadSponsor":"GlaxoSmithKline","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":42,"enrolmentType":"ACTUAL","siteCount":11,"recruitingSiteCount":0,"countries":["Canada","Panama","United States"]}],"started":"2023-10-24","startedType":"actual","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06077877/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}